A Clinical Score for Predicting the Paroxysmal Supraventricular Tachycardia’s Recurrence Risk; a Retrospective Cross-sectional Study
Archives of Academic Emergency Medicine,
Vol. 11 No. 1 (2023),
15 November 2022
,
Page e2
https://doi.org/10.22037/aaem.v11i1.1825
Abstract
Introduction: Identifying prognostic variables associated with the probability of recurrent paroxysmal supraventricular tachycardia (PSVT) would aid decision-making regarding disposition of the patients. This study aims to develop a clinical scoring system to predict PSVT recurrence after adenosine administration in the emergency department (ED).
Methods: This retrospective cross-sectional study was conducted on patients who were referred to the emergency department of Ramathibodi Hospital, a university-affiliated super-tertiary care hospital in Bangkok, Thailand, with diagnosis of PSVT during a 10-year period from 01 January 2010 until 31 December 2020. The cases were divided into recurrent and non-recurrent PSVT based on the response to standard treatment and the independent predictors of recurrence were studied using multivariable logistic regression analysis.
Results: 264 patients were diagnosed with PSVT and successfully converted by adenosine. 24 (9.1%) had recurrent PSVT, and 240 (90.9%) had no recurrent PSVT in the same ED visit. The risk of PSVT recurrence in ED corresponded with the history of hypertension (p = 0.059), valvular heart disease (p = 0.052), heart rate ≥ 100 (p = 0.012), and systolic blood pressure < 100 after electrocardiogram (ECG) converted to sinus rhythm (p = 0.022) and total dose of adenosine (p = 0.002). We developed a clinical prediction score of PSVT recurrence with an accuracy of 79.5%. A score of 0 (low risk), 1–2 (moderate risk), and > 2 (high risk) had a positive likelihood ratio (LR+) of 0.31, 0.56 and 2.33, respectively.
Conclusion: It seems that, using the PSVT recurrence score we could screen the high-risk patients for PSVT recurrence (score>2) who need to be observed for at least 6-12 hours and receive cardiologist consultation in ED. In addition, the moderate and low-risk group (score 0-2) need to be observed for 1 hour and can be discharged from ED.
- Tachycardia, Supraventricular
- Recurrence
- Emergency Service, Hospital
- Adenosine
- Clinical Decision Rules
How to Cite
References
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133(14):e506-74.
Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardia the task force for the management of patients with supraventricular tachycardia of the European society of Cardiology (ESC) developed in collaboration with the association for European paediatric and congenital Cardiology (AEPC). Eur Heart J. 2020;41(5):655-720.
Murman DH, McDonald AJ, Pelletier AJ, Camargo Jr CA. US emergency department visits for supraventricular tachycardia, 1993–2003. Acad Emerg Med. 2007;14(6):578-81.
Faulds D, Chrisp P, Buckley MM. Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia. Drugs. 1991;41(4):596-624.
Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20(7):717-21.
Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16_Suppl_2):S366-S468.
Brubaker S, Long B, Koyfman A. Alternative treatment options for atrioventricular-nodal-reentry tachycardia: an emergency medicine review. J Emerg Med. 2018;54(2):198-206.
Piyanuttapull S, Patarananakul P. Recurrence rate of PSVT (paroxysmal supraventricular tachycardia) in Rajavithi emergency department. J Med Assoc Thai. 2013;96(Suppl 3):S47-53.
Dewland TA, Oesterle A, Stein J, Marcus GM. Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department. J Interv Card Electrophysiol. 2017;49(2):103-9.
Tangkulpanich P, Yuksen C, Kongchok W, Jenpanitpong C. Clinical Predictors of Emergency Department Revisits within 48 Hours of Discharge; a Case Control Study. Arch Acad Emerg Med. 2021;9(1):e1.
Luber S, Brady WJ, Joyce T, Perron AD. Paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med. 2001;19(1):40-2.
Althunayyan SM, Khan AA, Samarkandi OA. Emergency department visits for paroxysmal supraventricular tachycardia in Saudi Arabia. Saudi J Anaesth. 2018;12(4):521-8.
Sawhney V, Corden B, Abdul-Mukith K, Harris T, Schilling RJ. Are patients admitted to emergency departments with regular supraventricular tachycardia (SVT) treated appropriately? Clin Med (Lond). 2013;13(2):146-8.
Honarbakhsh S, Baker V, Kirkby C, Patel K, Robinson G, Antoniou S, et al. Safety and efficacy of paramedic treatment of regular supraventricular tachycardia: a randomised controlled trial. Heart. 2017;103(18):1413-8.
Wegner FK, Habbel P, Schuppert P, Frommeyer G, Ellermann C, Lange PS, et al. Predictors of AVNRT Recurrence After Slow Pathway Modification A Case Control Study. Int Heart J. 2021;62(1):72-7.
- Abstract Viewed: 479 times
- pdf Downloaded: 864 times
